Literature DB >> 19250777

In vitro antimicrobial susceptibility of Mycoplasma bovis isolated in Israel from local and imported cattle.

Irena Gerchman1, Sharon Levisohn, Inna Mikula, Inna Lysnyansky.   

Abstract

Monitoring of susceptibility to antibiotics in field isolates of pathogenic bovine mycoplasmas is important for appropriate choice of treatment. Our study compared in vitro susceptibility profiles of Mycoplasma bovis clinical strains, isolated during 2005-2007 from Israeli and imported calves. Minimal inhibitory concentration (MIC) values were determined for macrolides by the microbroth dilution test, for aminoglycosides by commercial Etest, and for fluoroquinolones and tetracyclines by both methods. Notably, although correlation between the methods was generally good, it was not possible to determine the MIC endpoint for enrofloxacin-resistant strains (MIC > or =2.5 microg/ml in the microtest) by Etest. Comparison of antibiotic susceptibility profiles between local and imported M. bovis strains revealed that local strains were significantly more resistant to macrolides than most isolates from imported animals, with MIC(50) of 128 microg/ml vs. 2 microg/ml for tilmicosin and 8 microg/ml vs. 1 microg/ml for tylosin, respectively. However, local strains were more susceptible than most imported strains to fluoroquinolones and spectinomycin. Difference in susceptibility to tetracycline, doxycycline and oxytetracycline between local and imported strains was expressed in MIC(90) values for imported strains in the susceptible range compared to intermediate susceptibility for local strains. The marked difference in susceptibility profiles of M. bovis strains isolated from different geographical regions seen in this study emphasizes the necessity for performing of the antimicrobial susceptibility testing periodically and on a regional basis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250777     DOI: 10.1016/j.vetmic.2009.01.028

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  14 in total

1.  Development and evaluation of a novel single-nucleotide-polymorphism real-time PCR assay for rapid detection of fluoroquinolone-resistant Mycoplasma bovis.

Authors:  M Ben Shabat; I Mikula; I Gerchman; I Lysnyansky
Journal:  J Clin Microbiol       Date:  2010-06-09       Impact factor: 5.948

2.  Rapid detection of a point mutation in the parC gene associated with decreased susceptibility to fluoroquinolones in Mycoplasma bovis.

Authors:  I Lysnyansky; I Mikula; I Gerchman; S Levisohn
Journal:  Antimicrob Agents Chemother       Date:  2009-08-31       Impact factor: 5.191

3.  16S rRNA gene mutations associated with decreased susceptibility to tetracycline in Mycoplasma bovis.

Authors:  E Amram; I Mikula; C Schnee; R D Ayling; R A J Nicholas; R S Rosales; S Harrus; I Lysnyansky
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Relationship between Antimicrobial Susceptibility and Multilocus Sequence Type of Mycoplasma bovis Isolates and Development of a Method for Rapid Detection of Point Mutations Involved in Decreased Susceptibility to Macrolides, Lincosamides, Tetracyclines, and Spectinomycin.

Authors:  Eiji Hata; Takehiro Harada; Megumi Itoh
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

5.  Characterization of in vivo-acquired resistance to macrolides of Mycoplasma gallisepticum strains isolated from poultry.

Authors:  Irena Gerchman; Sharon Levisohn; Inna Mikula; Lucía Manso-Silván; Inna Lysnyansky
Journal:  Vet Res       Date:  2011-08-02       Impact factor: 3.683

6.  Overall decrease in the susceptibility of Mycoplasma bovis to antimicrobials over the past 30 years in France.

Authors:  Anne V Gautier-Bouchardon; Séverine Ferré; Dominique Le Grand; Agnès Paoli; Emilie Gay; François Poumarat
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

7.  Antibiotic susceptibility profiles of Mycoplasma bovis strains isolated from cattle in Hungary, Central Europe.

Authors:  Kinga M Sulyok; Zsuzsa Kreizinger; Lilla Fekete; Veronika Hrivnák; Tibor Magyar; Szilárd Jánosi; Nóra Schweitzer; Ibolya Turcsányi; László Makrai; Károly Erdélyi; Miklós Gyuranecz
Journal:  BMC Vet Res       Date:  2014-10-25       Impact factor: 2.741

Review 8.  Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.

Authors:  Inna Lysnyansky; Roger D Ayling
Journal:  Front Microbiol       Date:  2016-04-27       Impact factor: 5.640

9.  Antimicrobial susceptibility and molecular characterization of macrolide resistance of Mycoplasma bovis isolates from multiple provinces in China.

Authors:  Ling-Cong Kong; Duo Gao; Bo-Yan Jia; Zi Wang; Yun-Hang Gao; Zhi-Hua Pei; Shu-Ming Liu; Jiu-Qing Xin; Hong-Xia Ma
Journal:  J Vet Med Sci       Date:  2015-09-07       Impact factor: 1.267

10.  Immunoproteomic identification of MbovP579, a promising diagnostic biomarker for serological detection of Mycoplasma bovis infection.

Authors:  Farhan Anwar Khan; Muhammad Faisal; Jin Chao; Kai Liu; Xi Chen; Gang Zhao; Harish Menghwar; Hui Zhang; Xifang Zhu; Muhammad Asif Rasheed; Chenfei He; Changmin Hu; Yingyu Chen; Eric Baranowski; Huanchun Chen; Aizhen Guo
Journal:  Oncotarget       Date:  2016-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.